Olinciguat Granted Orphan Drug Status for Sickle Cell Disease
Olinciguat is a soluble guanylate cyclase stimulator currently in Phase 2 development.
Sickle Cell Disease
Siklos Approved for Pediatric Patients With Sickle Cell Anemia
This is the first FDA approval of hydroxyurea for use in pediatric patients with sickle cell disease.
Sickle Cell Disease Treatment Endari Soon to Be Available
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
